

PERIPHERAL ARTERIAL DISEASE VOLUME II

Table of Contents

INTRODUCTION	1
THE DISEASE	1
SYMPTOMS AND CONSEQUENCES	1
INTERMITTENT CLAUDICATION IS UNCOMMON	2
MOBILITY IMPAIRMENT, MUSCLE AND NERVE DAMAGE	3
MOBILITY IMPAIRMENT	3
ISCHEMIA CAUSES MUSCLE AND NERVE DAMAGE	3
ISCHEMIC DAMAGE—A FACTOR IN CARDIOVASCULAR MORTALITY?.....	4
MORTALITY	5
HEART ATTACK AND STROKE—THE MAIN CAUSES OF DEATH.....	5
HIGH FIVE- AND 10-YEAR MORTALITY	5
AN INDICATOR OF SILENT CARDIOVASCULAR AND CEREBROVASCULAR DISEASE	5
INITIAL DIAGNOSIS—ABI	6
DISEASE SEVERITY ASSOCIATED WITH LOWER ABI	6
PAD IS NOT BENIGN	7
DISEASE PROGRESSION—RECENT RESEARCH	8
TREATMENT OPTIONS	8
REVASCULARIZATION	9
DIAGNOSTIC MODALITIES	10
INVASIVE	10
<i>Angiography—The Gold Standard</i>	10
<i>Intravascular Ultrasound</i>	10
NONINVASIVE DIAGNOSTIC MODALITIES	11
<i>Duplex Ultrasound</i>	11
<i>Magnetic Resonance Angiography (MRA)</i>	11
<i>CT Angiography</i>	12
REVASCULARIZATION METHOD DEPENDS ON DISEASE SEVERITY, LOCATION AND TYPE OF LESION	12
TYPES OF ATHEROSCLEROSIS	13
TYPE I—AORTOILIAC DISEASE.....	13
TYPE II DISEASE	13

TYPE III—DIFFUSE DISEASE	13
SYSTEMS FOR CATEGORIZING DISEASE SEVERITY	13
FONTAINE DISEASE CLASSIFICATION SYSTEM	14
RUTHERFORD CLASSIFICATION SYSTEM	14
INTERVENTIONAL GUIDELINES AND LESION CLASSIFICATION SYSTEMS	
.....	14
TASC	15
AHA AND SIR	15
DEFINITION OF SUCCESS.....	15
PROBLEMS COMPARING DIFFERENT REVASCULARIZATION METHODS	
.....	17
QUALITY OF LIFE.....	17
NEW METHODS FOR MEASURING QUALITY OF LIFE.....	17
LOWER EXTREMITY GRADING SCALE (LEGS)	17
PERIPHERAL ARTERY QUESTIONNAIRE (PAQ)	18
THE ALEVE REGISTRY	18
BYPASS SURGERY.....	19
THE GOLD STANDARD	19
ADVANTAGES AND DISADVANTAGES OF BYPASS SURGERY	19
INDICATIONS FOR BYPASS SURGERY.....	20
TYPE OF DISEASE AND LESIONS DETERMINE USE OF SURGERY	21
OUTCOME MEASUREMENTS	22
<i>Location of Surgery and Type of Graft Affect Patency.....</i>	<i>22</i>
COMPLICATIONS	23
RESTENOSIS—BYPASS.....	24
GRAFTS	24
TYPES	24
MANUFACTURERS.....	25
BLOOD CLOTS	25
CLOT REMOVAL.....	26
<i>Thrombolysis.....</i>	<i>26</i>
<i>Thrombectomy Devices.....</i>	<i>27</i>
ENDOVASCULAR THERAPY	27
PTA.....	29
INDICATIONS AND CONTRAINDICATIONS	29
VARIABLES IN SUCCESSFUL PTA.....	30
COMPLICATIONS	30
PREVENTION OF BLOOD CLOTS.....	32

ANTIPLATELETS	32
<i>Reduce Risk of Vascular Occlusion</i>	33
<i>Protective Effect Against Heart Attack, Stroke and Death</i>	33
<i>Plavix Reduces Risk of Adverse Events in Coronary Interventions</i>	33
<i>Plavix Clinical Trials in PTA and Peripheral Bypass</i>	33
ANTICOAGULANTS	34
RESTENOSIS—PTA	34
HIGHER AFTER PTA THAN BYPASS	34
MECHANISMS OF RESTENOSIS	35
<i>Intimal Hyperplasia</i>	35
<i>Elastic Recoil</i>	35
<i>Arterial Remodeling</i>	35
LATE RESTENOSIS	36
PTA BALLOON CATHETERS AND RELATED ANGIOPLASTY PRODUCTS 36	
TYPES OF PRODUCTS	36
MANUFACTURERS	36
STENTS	36
BALLOON-EXPANDABLE	36
SELF-EXPANDABLE	37
COMPLICATIONS	37
ATHERECTOMY	38
ATHERECTOMY DEVICES	39
<i>SilverHawk System</i>	40
ILIAC ARTERIES AND AORTOILIAC DISEASE	40
ENDOVASCULAR HAS BECOME FIRST-LINE THERAPY	41
GENERAL PRINCIPLES FOR CHOICE OF INTERVENTION	42
TYPES OF LESIONS AND TREATMENT CHOICE	42
PTA COMPARED TO BYPASS SURGERY	44
PTA MORE COST-EFFECTIVE IN TREATMENT OF IC	45
ILIAC STENTING	45
STENTS IMPROVE PTA OUTCOMES	45
OCCLUSIONS	46
LOW RESTENOSIS RATES	46
DISEASE PATTERN AND GENDER AFFECT OUTCOME AND COMPLICATIONS	46
SELECTIVE STENTING IS MORE COST-EFFECTIVE THAN PTA ALONE	46
PRIMARY STENTING IS THE NORM	47
DEBATE OVER PRIMARY STENTING	47
<i>Cost-Effectiveness</i>	48
STENTS CURRENTLY EMPLOYED IN ILIAC DISEASE.....	48
BALLOON-EXPANDABLE STENTS	48

SELF-EXPANDING STENTS	49
<i>Comparison of SMART and WALLSTENT-CRISP US Study</i>	50
PERIPHERAL COVERED STENTS	51
STENT-GRAFTS IN TREATMENT OF ILIAC OCCLUSIVE DISEASE.....	52
<i>Potential Complications and Costs</i>	52
<i>Early Stent-Grafts Had Poor Patency and High Rate of Complications</i>	53
PROMISING RESULTS WITH NEW STENT-GRAFTS.....	53
<i>Viabahn Endoprosthesis</i>	53
<i>Early Results in Treatment of Diffuse Aortoiliac Disease—Wallgraft, Viabahn and aSpire</i>	54
FEMOROPOPLITEAL DISEASE	55
THE ACHILLES HEEL OF THE VASCULAR SPECIALIST.....	56
CHARACTERISTICS	56
ANGIOPLASTY IN FEMOROPOPLITEAL DISEASE	57
COMPARISON OF FEMOROPOPLITEAL AND AORTOILIAC PTA	58
DISEASE DIFFUSION AND RUNOFF STATUS—KEYS TO SUCCESS	59
COMPARISON OF FEMOROPOPLITEAL PTA AND BYPASS SURGERY	60
<i>Mode of Failure</i>	61
<i>Cost-Effectiveness and Quality of Life</i>	62
<i>PTA — Generally the Preferred Initial Treatment Strategy</i>	63
COMBINED REVASCULARIZATION APPROACH: PTA FOLLOWED BY SURGERY	63
<i>Total Patency—A Measure of the End Result of All Invasive Treatments</i>	64
<i>Invasive Treatment Might Delay Development of CLI</i>	64
FEMOROPOPLITEAL STENTING.....	65
PATENCY AND RESTENOSIS RATES	66
<i>Lesion Location Affects Restenosis</i>	66
VARIABLES IN SUCCESSFUL SFA STENTING	66
<i>Poor Patency with Stainless Steel Stents</i>	66
COMPARISON OF STENTING WITH BYPASS SURGERY	68
<i>Bypass—Higher Patency But Higher Morbidity and Mortality</i>	70
RESULTS OF OLDER SFA STENT STUDIES NOT COMPARABLE TO THOSE OF RECENT STUDIES	70
NEW DESIGNS AND MATERIALS.....	71
ADVANCES IN DELIVERY TECHNOLOGY AND TECHNIQUE	71
IMPACT OF ANTI-CLOTTING THERAPY	71
STENTS EMPLOYED IN THE INFRAINGUINAL ARTERIES.....	71
MOST ARE USED OFF-LABEL	71
NITINOL STENTS	72
<i>Restenosis Rates Considerably Lower</i>	72
<i>Excellent Patency May Change the Role of Stenting in Femoropopliteal Disease</i> ..	74
STENT FRACTURE	74

A NOTE OF CAUTION REGARDING ROLE OF CURRENT STENT TECHNOLOGY IN THE SFA	75
STENT-GRAFTS IN THE FEMORAL ARTERIES	77
DRUG ELUTING STENTS	79
PROMISING EARLY DATA IN THE SFA	79
<i>SIROCCO I</i>	79
<i>SIROCCO II</i>	79
JOSTENT INFRAPLOPITEAL FEASIBILITY STUDY	80
STENT FRACTURE AND LATE RESTENOSIS RATES RAISE QUESTIONS	80
EXPECT SLOWER ADOPTION OF DES IN THE SFA	81
NEW STENT CONCEPTS—MATERIALS, COATINGS AND ABSORBABLE STENTS	81
CRYOPLASTY—A NEW APPROACH TO TREATING SFA DISEASE	81
TOTAL OCCLUSIONS	82
NEW TREATMENT MODALITIES	83
<i>Frontrunner</i>	83
<i>Safe-Cross Radiofrequency Total Occlusion Crossing System</i>	84
<i>CrossPoint TransAccess Catheter</i>	85
<i>Excimer Laser in Total Occlusions</i>	86
TIBIOPERONEAL DISEASE	88
LIMITED INDICATIONS FOR PTA	88
AGE AND SERIOUS CO-MORBIDITIES COMPLICATE TREATMENT OF TIBIAL DISEASE	89
PTA FOR LIMB SALVAGE AND PAIN RELIEF	89
STENTS IN THE TIBIAL ARTERIES	90
CRITICAL LIMB ISCHEMIA	90
PTA AS PRIMARY THERAPY—RECENT EVIDENCE	90
SURGERY AND LIMB SALVAGE IN CLI	92
<i>In Diabetic and Non-Diabetic Patients</i>	92
<i>Pedal Bypass Grafting in Patients with Serious Co-Morbidities</i>	93
<i>In ESRD and Non-ESRD Patients</i>	94
ENDOVASCULAR MAY BECOME PRIMARY THERAPY IN LIMB SALVAGE	94
LIMB SALVAGE WITH CUTTING BALLOON AND EXCIMER LASER	94
CUTTING BALLOON	95
<i>Promising Early Evidence in Limb Salvage</i>	95
<i>Restenosis in Bypass Grafts</i>	96
EXCIMER LASER	96
<i>LACI Trial</i>	96
TRADITIONAL REVASCLARIZATION STRATEGIES COMPARED WITH CUTTING BALLOON AND LASER	97
<i>LACI Equivalent Study</i>	98
<i>Ansel Cutting Balloon Study</i>	98

AMPUTATION.....	99
MORBIDITY AND MORTALITY	99
HIGH COST TO SOCIETY	99
AMPUTATION COMPARED WITH REVASCULARIZATION—MORBIDITY, MORTALITY AND COST	99
ARGUMENT FOR EARLIER AND MORE FREQUENT INTERVENTIONS ..	100
PAD A SIGNIFICANT MARKET OPPORTUNITY	101
MARKET TO INCREASE WITH THE GRAYING OF AMERICA	101
PAD UNDERDIAGNOSED AND UNDERTREATED.....	101
LESS THAN 20% OF PAD PATIENTS ESTIMATED TO HAVE BEEN DIAGNOSED	102
CATALYSTS FOR CHANGE	102
<i>NHLBI and Coalition of Professional and Nonprofit Vascular Groups.....</i>	<i>102</i>
<i>AHA Launches First PAD Program</i>	<i>103</i>
INTERVENTIONAL PROCEDURES 1983-2000.....	103
PERIPHERAL BYPASS PROCEDURES.....	103
INCREASING UTILIZATION OF ENDOVASCULAR PROCEDURES	104
<i>Factors Stimulating Growth</i>	<i>104</i>
CHANGING PRACTICE—ENDOASCULAR NOW PRIMARY TREATMENT FOR IC	105
THE NUMBER OF PAD-RELATED AMPUTATIONS REMAINS HIGH	106
<i>Disease Often Not Diagnosed Until the Advanced Stages.....</i>	<i>107</i>
UNTAPPED MARKET FOR INTERVENTIONAL THERAPY	107
ESTIMATED MARKET FOR INTERVENTIONAL THERAPY BY DISEASE SEVERITY—2000	107
ESTIMATED MARKET FOR BYPASS AND ENDOVASCULAR THERAPY BY DISEASE SEVERITY—2000.....	108
ESTIMATED BYPASS MARKET POTENTIAL IN MILLIONS OF LIMBS BY DISEASE SEVERITY—2000	109
ESTIMATED ENDOVASCULAR MARKET POTENTIAL IN MILLIONS OF LIMBS BY DISEASE SEVERITY—2000.....	110
MARKET POTENTIAL FOR INTERVENTIONAL THERAPY 2000-2020.....	111
COMPARISON OF CURRENT MARKET FOR PRIMARY BYPASS SURGERY WITH POTENTIAL MARKET—2003.....	112
COMPARISON OF BYPASS MARKET GROWTH PROJECTIONS 2000-2010	112
CURRENT BYPASS MARKET AND POTENTIAL MARKET AS PERCENTAGE OF PAD PATIENTS DIAGNOSED INCREASES TO 30%	112
CURRENT BYPASS MARKET AND POTENTIAL MARKET AS PERCENTAGE OF PAD PATIENTS DIAGNOSED INCREASES TO 35%	113
COMPARISON OF CURRENT MARKET FOR PRIMARY ENDOVASCULAR THERAPY WITH POTENTIAL MARKET—2003	113

COMPARISON OF ENDOVASCULAR MARKET GROWTH PROJECTIONS	114
2000-2010	114
CURRENT ENDOVASCULAR MARKET AND POTENTIAL MARKET AS PERCENTAGE OF PAD PATIENTS DIAGNOSED INCREASES TO 30%	114
CURRENT ENDOVASCULAR MARKET AND POTENTIAL MARKET AS PERCENTAGE OF PAD PATIENTS DIAGNOSED INCREASES TO 35%	114
PAD MARKET POTENTIAL FOR PRIMARY AND REDO BYPASS SURGERY—2003	114
PAD MARKET POTENTIAL FOR PRIMARY AND REDO BYPASS SURGERY—2000-2020	115
PAD MARKET POTENTIAL FOR PRIMARY AND REDO ENDOVASCULAR THERAPY—2003	115
PAD MARKET POTENTIAL FOR PRIMARY AND REDO ENDOVASCULAR THERAPY—2000-2020	116
COMPANY INFORMATION	116
REFERENCES	116
LIST OF STUDIES/ACRONYMS	116
INDEX OF TABLES AND FIGURES	116
GLOSSARY	116
TRADEMARKS	116
DISCLOSURE STATEMENT	116
CONTACT INFORMATION	116